期刊文献+

人类Survivin基因真核表达载体的构建及其在K562细胞中的表达

Construction of human eukaryotic vector with expression of survivin in K562 cells
原文传递
导出
摘要 目的 构建带有绿色荧光蛋白的Survivin基因真核表达载体pIRES2-EGFP/Survivin,并转染K562细胞。方法 以 pDNR/Survivin质粒为模板,PCR扩增Survivin基因,T-A 克隆,亚克隆至pIRES2-EGFP上,并对重组表达载体进行酶切、测序鉴定。采用Superfect转染试剂转染K562细胞。提取细胞RNA,RT-PCR检测Survivin基因mRNA表达。结果 经限制性酶切鉴定及测序分析证实pIRES2-EGFP/Survivin载体序列正确;荧光显微镜下可见转染的K562细胞有绿色荧光蛋白的表达,RT-PCR证实转染细胞中存在Survivin基因mRNA的表达。结论 pIRES2-EGFP/Survivin表达载体构建成功,并在K562细胞内成功表达。 Objective To construct an eukaryotic vector with expression of human survivin gene with green fluorescent protein which is named pIRES2-EGFP/survivin and transfected into K562 cell line. Methods Using pDNR/Survivin plasmid as a template, the full length of survivin cDNA was amplified by PCR and subsequently cloned into T-A vector and then subcloned into pIRES2-EGFP vector. After identified by digestion of restrictive endonucleases, pIRES2-EGFP/survivin was further confirmed by sequencing. Then it was transfected into K562 cells with superfect reagents. The mRNA was isolated and survivin gene was detected by Western blotting. Results The exact sequences of pIRES2-EGFP/survivin vector were confirmed by digestion of restrictive endonucleases and sequencing. After transfection, the expressions of green fluorescent protein were present. The mRNA expression of survivin has been detected in transfected cells by RT-PCR. Conclusion The vector pIRES2-EGFP/survivin has been constructed and could express survivin gene in K562 cells successfully.
出处 《白血病.淋巴瘤》 CAS 2009年第11期647-649,共3页 Journal of Leukemia & Lymphoma
基金 山西省青年基金(2007021052) 山西医科大学青年基金(2005-47) 山西医科大学第二医院博士启动基金(200614)
关键词 SURVIVIN基因 真核表达载体 转染 K562细胞 Survivin gene Eukaryotic expression vector Transfect K562 cells
  • 相关文献

参考文献7

  • 1张晓晖,夏凌辉,刘仲萍,魏文宁,胡豫,宋善俊.Survivin致敏的树突状细胞疫苗激活抗白血病T细胞的实验研究[J].中国实验血液学杂志,2003,11(1):66-69. 被引量:3
  • 2Colnaghi R, Connell CM, Barrett RM, et al. Separating the Anti-apoptotic and Mitotic Role. J Biol Chem, 2006, 281: 33450-33456.
  • 3Hinz T, Buchholz C J, van der Stappen T, et al. Thomas manufacturing and quality control of cell-based tumor vaccines: a scientific and a regulatory perspective. J Immunother, 2006, 29: 472-476.
  • 4Nagara J, Sriniva S, Pisare V, et al. Dendritic ceU-based full-length survivin vaccine in treatment of experimental tumors. Immunol, 2007, 30: 169-179.
  • 5Zeis M, Siegel S, Wagner A, et al. Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells. J Immunol,2003, 170: 5391-5397.
  • 6Idenoue S, Hirohashi Y, Torigoe T, et al. A potent immunogenic general cancer vaccine that targets Survivin, an inhibitor of apoptosis proteins. Clin Cancer Res, 2005,11: 1474-1482.
  • 7Cormack BP, Valdivia RH, Falkow S. FACS-optimized mutants of the green fluorescent protein (GFP). Gene, 1996, 173: 33-38.

二级参考文献12

  • 1[1]Kawasaki H, Altieri DC, Lu CD, et al. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res, 1998; 58:5071 - 5074
  • 2[2]Orsini E, Foa R. Dendritic cell generation for leukemia immunotherapy. Leuk Res, 2002; 26:409- 410
  • 3[3]Adida C, Crotty PL, McGrath J, et al. Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol, 1998; 152:43 - 49
  • 4[4]Altieri DC. The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med, 2001; 7:542 - 547
  • 5[5]Wall NR, Beck FM, Al-Katib AM, et al. Treatment-induced expression of anti-apoptotic proteins in WSU-CLL, a human chronic lymphocytic leukemia cell line. J Drug Target, 2001; 9:329 - 339
  • 6[6]Carter BZ, Milella M, Altieri DC, et al. Cytokine-regulated expression of survivin in myeloid leukemia. Blood, 2001; 97: 2784 -2790
  • 7[7]Hasel T, Yoshimura R, Wada S, et al. Dendritic cells, generated in vitro, are immunocompetent and very useful in the induction of specific cytotoxic T lymphocyte activity. Transplant Proc, 2001;33:3814 - 3815
  • 8[8]Takahashi T. Dendritic cell therapy. Nippon Rinsho, 2001; 59:2421 - 2426
  • 9[9]Rousseau RF, Bollard CM, Heslop HE. Gene therapy for paediatric leukaemia. Expert Opin Biol Ther, 2001; 1:663 - 674
  • 10[10]Reid DC. Dendritic cells and immunotherapy for malignant disease.Br J Haematol, 2001; 112:874- 887

共引文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部